ADMA Biologics (ADMA) 10-Q2019 Q1 Quarterly report

Filed: 8 May 19, 5:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: AC, ACA, accessed, advisor, antiviral, appeal, ASCENIV, automatically, Biolife, body, broadly, budget, burden, California, Cardinal, CCPA, Circuit, Committee, complement, confirm, congenital, context, conversion, core, creation, creditor, curve, degree, Distinguishing, District, divert, dividend, embedded, EPS, expenditure, explored, exploring, extinguishment, family, FDAapproved, feature, fluid, formal, freestanding, furlough, Guaranty, harbor, Hedging, HHS, holder, identical, identification, immaterial, immunology, incremental, indexed, instrument, interpreted, lawfully, lengthy, Lordi, LP, methodology, multiplied, NJ, Northern, notice, nurse, OAI, organization, originally, overcome, owner, package, pledged, political, potency, prepaid, prepay, privy, profile, prolonged, propose, proposed, Ramsey, redemption, reemergence, renewed, residual, reverse, Roswell, round, saturation, seizure, shipment, shut, shutdown, slra, stability, Statute, statutory, stayed, stop, struck, Sunshine, Supreme, tailored, tangible, teaching, tracked, tracking, trailing, treated, twelve, unamortized, unconstitutional, underabsorbed, unique, USPTO, VWAP, warrant, Webelieve, yield

Removed: academic, accelerated, achieving, active, affirmatively, allocation, applied, applying, approach, backup, billion, blended, bound, calendar, clarification, collectability, component, computing, consummated, consummation, CREAT, criterion, DGCL, director, disclose, enhancement, enriched, entirety, establishment, exclude, feedback, filer, finite, floor, forma, GHA, headcount, impacting, influenza, informational, inspectional, irrevocably, Korean, large, leased, liquidation, measurement, Ministry, modification, mortgage, negotiation, observer, opened, opening, operation, Oxford, passed, Pasteur, planning, plant, pro, ranged, reapply, refiling, reflect, relinquished, retire, saleable, Sanofi, shared, SK, sought, supplemented, Trademark, transferee, unabsorbed, validate, validation, waived, warehouse, Wilmington

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ADMA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2019	By:	/s/ Brian Lenz
	Name:	Brian Lenz
	Title:	Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)